MRVI · Maravai Lifesciences Holdings, Inc.

Track MRVI — free

$7.66 +0.01 (+0.13%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$1.97B

259.67M

Volume · Sep 30 3.61M Avg daily vol (3M) 3.24M

Up next

Next earnings call

Nov 3, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 7, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$208.78M

Trailing 12 months

Net income (TTM)

−$77.39M

Trailing 12 months

Revenue growth YoY

+8.5%

Year over year

Operating margin

-56.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-1.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$77.01M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.6%

Year over year · more shares

Price change (1Y)

+170.3%

Trailing year

Short interest

4.8%

Latest settlement · 4.7 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Maravai posted Q2 revenue of $51.4M (up 9% YoY) and raised full-year adjusted EBITDA guidance to $33–$35M on stronger TriLink growth, but maintained its revenue range, posted a $(21.6)M GAAP net loss that included a $3.0M loss on debt extinguishment, and flagged lumpiness in CDMO and large GMP orders that creates back-half uncertainty.

Bullish

+ Full-year 2026 adjusted EBITDA guidance raised to $33M–$35M from $30M–$32M on margin expansion.
+ TriLink added a record 67 new Discovery mRNA customers in Q2 and e-commerce delivered record quarterly revenue.
+ ModTail has reached more than 125 active customers within a year of launch and is being extended into GMP-grade.
+ Debt was refinanced in June, reducing borrowings to ~$150M with maturities extended to 2032.

Bearish

− Full-year revenue guidance was maintained at $205M–$215M rather than raised, citing lumpiness in CDMO and large GMP orders.
− TriLink CDMO revenue declined year-over-year in Q2.
− Management flagged that Q3 is inherently a lower revenue quarter and that large multi-million dollar orders can shift between quarters.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +59%

above

Price vs 50-day avg +9%

above

RSI (14) 58

neutral

MACD trend Positive

52-week position 78%

mid-range

Momentum

relative strength

Very Strong

1-month return +5%

trailing

6-month return +146%

trailing

YTD return +136%

this year

Relative strength +134%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $7 › 200d $5 — 50d above 200d

Institutional flow Accumulating

+12% holders QoQ · +45 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.76% of float · ▲ +12.9% MoM · 4.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

178 holders — mid 3-yr range

Squeeze score 64

elevated · 0–100

Fundamentals

Weak

Revenue growth −28%

Y/Y

Gross margin 18%

contracting

EPS growth +14%

Y/Y

Free cash flow $-70.7M

Balance sheet $74.9M

net debt

Quant / Vol

risk profile

Very High

Volatility 68%

annualized · 1-yr

Max drawdown −30%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 3

Latest guidance · from the Earnings Call filed Jun 30, 2026

Revenue · full year 2026 Initiated $205M – $215M

prior FY $185.74M midpoint +13.1% Y/Y

Guided vs delivered · last 3 settled

Total revenue full year 2023

guided $275M – $285M

guided $275M – $285M $288.95M Beat +3.2%

Full-year revenue guidance full year of 2022

guided $920M – $960M

guided $920M – $960M $883M Miss −6.1%

Total revenue 2021 full-year

guided $770M – $780M

guided $770M – $780M $799.24M Beat +3.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+59% Bullish

Price vs 50-day avg

+9% Bullish

RSI (14)

58 Neutral

MACD trend

Positive Bullish

52-week position

78% Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $7 › 200d $5 — 50d above 200d

Institutional flow Accumulating

+12% holders QoQ · +45 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.76% of float · ▲ +12.9% MoM · 4.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

178 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $3 Now $8 · 78% Range high $9

vs 200-day avg +59% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA (Non-GAAP financial measure) non-GAAP	$8.67M	Three Months Ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MRVI Maravai Lifesciences Holdings, Inc. this stock	$1.97B	+135.7%	-28.3%	—	4.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

178

% held: 54.2%
Net QoQ: +18.7M sh
Top holder: GTCR LLC

Held Float

View

Held by Funds

Fund positions

168

View

Short & Settlement

Short Interest Rising

Shares short

12.4M

Days to cover: 4.7d
Change: +1.4M sh

View

Short Volume

Short vol %

38%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

7.5K

Value: $55.0K
As of: Sep 3, 2026

View

Off-Exchange

Off-exchange %

47.6%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Apr 10, 2023

View

Financials

Revenue (FY)

$185.7M

Net income (FY): $-130.8M
EPS diluted: $-0.90

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 7, 2026
This year: 10

View

Proposed Sales

Value

$127.5K

Shares: 25.0K
Filed: Jun 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
MRVI	+3.9%	+4.9%	+146.3%	+0.3%	+135.7%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+4.6%	+4.8%	+134.1%	+0.8%	+123.9%

Key facts CIK 1823239 CUSIP 56600D107 13F (30d) 4 filings 4 filers Visit website Investor relations

MRVI · Maravai Lifesciences Holdings, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance